Jun 2026 (Q2 FY26) — Aug 5, 2026
Biodesix Q2 FY26 — Strong Revenue Growth and Margin Expansion
Read the full callBiodesix (BDSX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Biodesix earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 26.9 | +34.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -20.1 | +28.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$23.66 −4.25% · −$1.05
Performance +218.9% 1Y
1Y: $7.42 on 15 Oct 2025 → $23.66. High $30.6 (26 Aug 2026), low $5.46 (9 Jan 2026).
- Previous close
- $24.71
- 52-week range
- $5.46 – $30.6
- One year
- +240.43%
Overview
- Symbol
- BDSX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Biodesix earnings calls (BDSX)
Financials
What the filings say
Net profit, year on year: +37% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 18 | 20 | 18 | 20 | 22 | 29 | 26 | 27 |
| Operating profit | -9 | -7 | -9 | -10 | -7 | -2 | -6 | -5 |
| Operating margin | −47.3% | −32.5% | −50.9% | −48.5% | −32.4% | −6.8% | −24.3% | −20.1% |
| Other income | -2 | -2 | -2 | -2 | -2 | -2 | -2 | -2 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net profit | -10 | -8 | -11 | -11 | -9 | -4 | -8 | -7 |
| EPS ($ per share) | -1.40 | — | -1.52 | -1.56 | -1.16 | — | -0.81 | -0.71 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -227 | -259 | -302 | -367 | -420 | -462 | -498 |
| Total liabilities | 76 | 80 | 56 | 72 | 95 | 76 | 90 |
| Fixed assets | 2 | 3 | 4 | 6 | 28 | 28 | 25 |
| Total assets | 45 | 121 | 76 | 93 | 99 | 97 | 87 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -22 | -21 | -28 | -45 | -23 | -49 | -23 |
| Cash from investing | -2 | -3 | -3 | -4 | -23 | -3 | -0 |
| Cash from financing | 23 | 81 | 1 | 59 | 29 | 52 | 16 |
| Net cash flow | -1 | 57 | -30 | 10 | -17 | -0 | -7 |
| Capital expenditure | -1 | -2 | -2 | -3 | -23 | -3 | -0 |
| Free cash flow | -23 | -23 | -30 | -48 | -46 | -52 | -24 |
Insider filings
50 filings between Nov 10, 2025 and Sep 30, 2026.
Open market
decisions to buy or sellPurchases
$3.12M
6 purchases by 1 insider
Sales
$118.4K
20 sales by 5 insiders
Compensation
not trading decisions- 24
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| SCHULER JACK W | $3.12M | — | Aug 12, 2026 |
| Hutton Scott | — | $64.3K | Feb 23, 2026 |
| Cowie Robin Harper | — | $19.1K | Feb 23, 2026 |
| O'Kane Kieran | — | $15.3K | Feb 23, 2026 |
| Pestano Gary Anthony | — | $15.2K | Feb 23, 2026 |
| Vazquez Chris | — | $4.5K | Feb 23, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | PATIENCE JOHN Director | Option exercise | 1,360 | — |
| Aug 12, 2026 | SCHULER JACK W 10% owner | Purchase | 15,000 | $367.0K |
| Aug 11, 2026 | SCHULER JACK W 10% owner | Purchase | 13,700 | $328.9K |
| Aug 10, 2026 | SCHULER JACK W 10% owner | Purchase | 13,900 | $337.0K |
| Jun 30, 2026 | PATIENCE JOHN Director | Option exercise | 1,361 | — |
| Mar 31, 2026 | PATIENCE JOHN Director | Option exercise | 1,361 | — |
| Feb 23, 2026 | Vazquez Chris Chief Accounting Officer | Sale | 211 | $2.7K |
| Feb 23, 2026 | Hutton Scott President & CEO | Sale | 1,490 | $19.0K |
| Feb 23, 2026 | Cowie Robin Harper CFO, Sec'y & Treasurer | Sale | 535 | $6.8K |
| Feb 23, 2026 | O'Kane Kieran Chief Commercial Officer | Sale | 535 | $6.8K |
| Feb 23, 2026 | Pestano Gary Anthony Chief Development Officer | Sale | 556 | $7.1K |
| Feb 20, 2026 | Vazquez Chris Chief Accounting Officer | Option exercise | 563 | — |
| Feb 20, 2026 | Hutton Scott President & CEO | Option exercise | 4,844 | — |
| Feb 20, 2026 | O'Kane Kieran Chief Commercial Officer | Option exercise | 1,469 | — |
| Feb 20, 2026 | Pestano Gary Anthony Chief Development Officer | Option exercise | 1,528 | — |
| Feb 20, 2026 | Cowie Robin Harper CFO, Sec'y & Treasurer | Option exercise | 1,469 | — |
| Feb 10, 2026 | Cowie Robin Harper CFO, Sec'y & Treasurer | Sale | 941 | $9.5K |
| Feb 10, 2026 | Vazquez Chris Chief Accounting Officer | Sale | 101 | $1.0K |
| Feb 10, 2026 | O'Kane Kieran Chief Commercial Officer | Sale | 584 | $5.9K |
| Feb 10, 2026 | Pestano Gary Anthony Chief Development Officer | Sale | 540 | $5.4K |
| Feb 10, 2026 | Hutton Scott President & CEO | Sale | 3,559 | $35.9K |
| Feb 9, 2026 | Cowie Robin Harper CFO, Sec'y & Treasurer | Option exercise | 2,584 | — |
| Feb 9, 2026 | Hutton Scott President & CEO | Option exercise | 9,998 | — |
| Feb 9, 2026 | Vazquez Chris Chief Accounting Officer | Option exercise | 263 | — |
| Feb 9, 2026 | O'Kane Kieran Chief Commercial Officer | Option exercise | 1,600 | — |
| Feb 9, 2026 | Pestano Gary Anthony Chief Development Officer | Option exercise | 1,481 | — |
| Jan 26, 2026 | SCHULER JACK W 10% owner | Purchase | 20,000 | $236.1K |
| Jan 23, 2026 | SCHULER JACK W 10% owner | Purchase | 80,000 | $944.7K |
| Jan 22, 2026 | SCHULER JACK W 10% owner | Purchase | 82,465 | $903.6K |
| Jan 16, 2026 | Cowie Robin Harper CFO, Sec'y & Treasurer | Sale | 298 | $2.4K |
| Jan 16, 2026 | Vazquez Chris Chief Accounting Officer | Sale | 83 | $676 |
| Jan 16, 2026 | Pestano Gary Anthony Chief Development Officer | Sale | 298 | $2.4K |
| Jan 16, 2026 | O'Kane Kieran Chief Commercial Officer | Sale | 298 | $2.4K |
| Jan 16, 2026 | Hutton Scott President & CEO | Sale | 970 | $7.9K |
| Jan 15, 2026 | Hutton Scott President & CEO | Option exercise | 2,633 | — |
| Jan 15, 2026 | Cowie Robin Harper CFO, Sec'y & Treasurer | Option exercise | 805 | — |
| Jan 15, 2026 | Vazquez Chris Chief Accounting Officer | Option exercise | 219 | — |
| Jan 15, 2026 | Pestano Gary Anthony Chief Development Officer | Option exercise | 805 | — |
| Jan 15, 2026 | O'Kane Kieran Chief Commercial Officer | Option exercise | 805 | — |
| Jan 5, 2026 | PATIENCE JOHN Director | Option exercise | 1,143 | — |
| Nov 10, 2025 | Vazquez Chris Chief Accounting Officer | Sale | 13 | $99 |
| Nov 10, 2025 | Vazquez Chris Chief Accounting Officer | Option exercise | 31 | — |
| Nov 10, 2025 | Pestano Gary Anthony Chief Development Officer | Option exercise | 69 | — |
| Nov 10, 2025 | Pestano Gary Anthony Chief Development Officer | Sale | 23 | $175 |
| Nov 10, 2025 | O'Kane Kieran Chief Commercial Officer | Sale | 25 | $191 |
| Nov 10, 2025 | O'Kane Kieran Chief Commercial Officer | Option exercise | 75 | — |
| Nov 10, 2025 | Hutton Scott President & CEO | Sale | 189 | $1.4K |
| Nov 10, 2025 | Hutton Scott President & CEO | Option exercise | 611 | — |
| Nov 10, 2025 | Cowie Robin Harper CFO, Sec'y & Treasurer | Sale | 50 | $381 |
| Nov 10, 2025 | Cowie Robin Harper CFO, Sec'y & Treasurer | Option exercise | 158 | — |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for BIODESIX INC
Free account. Everything above stays public.
Write why you follow BIODESIX INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading